Visceral Medicine最新文献

筛选
英文 中文
Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review. 非酒精性脂肪肝的诊断和治疗:一个叙述性的回顾。
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-04-01 DOI: 10.1159/000519611
Elke Roeb
{"title":"Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.","authors":"Elke Roeb","doi":"10.1159/000519611","DOIUrl":"https://doi.org/10.1159/000519611","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing and strongly associated with the metabolic syndrome, especially with obesity. A subtype, nonalcoholic steatohepatitis (NASH), might progress to advanced fibrosis and cirrhosis. NASH patients have an increased all-cause mortality. First and foremost are malignancies, followed by cardiovascular diseases.</p><p><strong>Summary: </strong>The NAFLD fibrosis score and noninvasive liver stiffness measurement (transient hepatic elastography) are essential components for the diagnostic risk assessment of NAFLD patients. Other steatoses (alcohol, genetic disorders, drugs, toxins, malnutrition, etc.) must be considered in the differential diagnosis. So far, there is no approved liver-specific drug therapy with a proven effect on NAFLD for patients without diabetes mellitus. Obeticholic acid (FXR agonist), cenicriviroc (a dual inhibitor of the chemokine receptors (CCR), CCR2 and CCR5), acetyl-CoA carboxylase inhibitors, and several thyroid hormone analogs are the most advanced substances in clinical development in ongoing phase 2 and 3 studies.</p><p><strong>Key messages: </strong>Weight loss, physical training, and the screening and treatment of risk factors represent the cornerstones of NAFLD therapy. Treatment with glucagon-like peptide 1 analogs (e.g., liraglutide, semaglutide) and sodium-dependent glucose transporter 2 inhibitors can be recommended in patients with diabetes and NASH.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 2","pages":"126-132"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082206/pdf/vis-0038-0126.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Society Bulletins 社会公告
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-04-01 DOI: 10.1159/000524179
{"title":"Society Bulletins","authors":"","doi":"10.1159/000524179","DOIUrl":"https://doi.org/10.1159/000524179","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"154 - 158"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48909673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Confounding by Indication Is a Major Issue in the Available Evidence on Role of Portal Vein Resection in Patients Undergoing Curative Surgery for Klatskin Tumour. 门静脉切除在克拉特金肿瘤根治性手术中的作用的现有证据中,指征混淆是一个主要问题。
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-04-01 DOI: 10.1159/000517690
Shahab Hajibandeh, Shahin Hajibandeh, Karim Hassan, Sumera Baloch, Thomas Satyadas
{"title":"Confounding by Indication Is a Major Issue in the Available Evidence on Role of Portal Vein Resection in Patients Undergoing Curative Surgery for Klatskin Tumour.","authors":"Shahab Hajibandeh,&nbsp;Shahin Hajibandeh,&nbsp;Karim Hassan,&nbsp;Sumera Baloch,&nbsp;Thomas Satyadas","doi":"10.1159/000517690","DOIUrl":"https://doi.org/10.1159/000517690","url":null,"abstract":"Dear Editor, Visceral Medicine has recently published interesting articles on treatment strategies for improving outcomes in patients with Klatskin tumour [1–4]. We have a particular interest in these articles as we have systematically been reviewing the literature on outcomes of portal vein resection (PVR) in patients with Klatskin tumour undergoing curative surgical resection. Considering that Klatskin tumour has been the focus of recently published articles in Visceral Medicine, we recognized this as a great opportunity to discuss our findings. Klatskin tumour is a rare tumour with an annual incidence of 1 in 100,000 [5]. It accounts for up to 60% of cholangiocarcinomas [6]. Complete surgical resection with achievement of negative resection margins remains the only curative treatment [1]. However, longitudinal intraductal tumour extension and the risk of vascular encasement associated with Klatskin tumour would make achievement of negative resection margins challenging. Consequently, there have been ongoing efforts to identify appropriate surgical strategies targeting achievement of negative resection margins in cases with Klatskin tumour. Considering that the portal vein is involved (microscopically and macroscopically) in a conspicuous proportion of patients with Klatskin tumour [7], routine PVR during surgical resection of Klatskin tumour has been recommended by some authors for achievement of negative resection margins [8–10]. Nevertheless, because PVR is technically challenging and may be associated with significant morbidity and mortality, its routine use has been controversial. Two meta-analyses have previously compared outcomes of PVR and no PVR in patients with Klatskin tumour [11, 12]. However, most of the included studies in previous meta-analyses did not provide data on baseline characteristics of their included population. Knowledge about the baseline characteristics of patients undergoing curative surgery with PVR in comparison with those undergoing curative surgery without PVR is crucial to make meaningful conclusions.","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 2","pages":"133-136"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000517690","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip). 胃癌(胃脘痛、胃脘痛)热腹腔化疗的适应证。
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-04-01 DOI: 10.1159/000522604
Beate Rau, Linda Feldbrügge, Felix Gronau, Miguel Enrique Alberto Vilchez, Peter Thuss-Patience, Pierre Emmanuel Bonnot, Olivier Glehen
{"title":"Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip).","authors":"Beate Rau,&nbsp;Linda Feldbrügge,&nbsp;Felix Gronau,&nbsp;Miguel Enrique Alberto Vilchez,&nbsp;Peter Thuss-Patience,&nbsp;Pierre Emmanuel Bonnot,&nbsp;Olivier Glehen","doi":"10.1159/000522604","DOIUrl":"https://doi.org/10.1159/000522604","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is associated with a poor prognosis mostly due to peritoneal metastasis, which will develop in time during the patient's disease history. To prevent and treat peritoneal metastasis, different kinds of treatment regimens have been described.</p><p><strong>Summary: </strong>In this review, we addressed two main topics - prophylaxis and treatment of peritoneal metastasis in GC. Prevention should be directed towards diminishing cancer cell spillage and reducing adherence of cancer cells to the abdominal cavity. Postoperative washing of the abdomen with or without chemotherapy and additional heat are herein discussed.</p><p><strong>Key messages: </strong>Treatment of existing peritoneal metastasis is effective in patients with limited disease and tumour spread. Cytoreductive surgery including resection of peritoneal metastasis followed directly with hyperthermic intraperitoneal chemotherapy can increase overall survival and progression-free survival in selected patients. Drugs, duration and time schedules of intraperitoneal chemotherapy are reviewed and presented. Intraperitoneal chemotherapy seems to improve the prognosis of patients with GC and peritoneal metastasis after complete resection of both primary and metastatic tumours.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 2","pages":"81-89"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082209/pdf/vis-0038-0081.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Integration of Cytoreductive Surgery and Perioperative Chemotherapy into the Multidisciplinary Management of Intra-Abdominal Cancer. 细胞减缩手术与围手术期化疗在腹内癌多学科治疗中的结合。
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-04-01 DOI: 10.1159/000522605
Paul H Sugarbaker
{"title":"Integration of Cytoreductive Surgery and Perioperative Chemotherapy into the Multidisciplinary Management of Intra-Abdominal Cancer.","authors":"Paul H Sugarbaker","doi":"10.1159/000522605","DOIUrl":"https://doi.org/10.1159/000522605","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 2","pages":"79-80"},"PeriodicalIF":1.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082172/pdf/vis-0038-0079.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Continuing Progress in the Interdisciplinary Management of Peritoneal Metastases 腹膜转移瘤跨学科治疗的持续进展
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-03-08 DOI: 10.1159/000523760
B. Rau, O. Glehen, P. Sugarbaker, M. H. Choudry, Y. Yonemura, D. Morris, S. Stintzing, D. Ryan
{"title":"Continuing Progress in the Interdisciplinary Management of Peritoneal Metastases","authors":"B. Rau, O. Glehen, P. Sugarbaker, M. H. Choudry, Y. Yonemura, D. Morris, S. Stintzing, D. Ryan","doi":"10.1159/000523760","DOIUrl":"https://doi.org/10.1159/000523760","url":null,"abstract":"aDepartment of Surgery, Campus Charité Mitte/Campus Virchow Klinikum CCM/CVK, Berlin, Germany; bDepartment of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon, Lyon, France; cProgram in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA; dDepartment of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; eDivision of Surgical Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA, USA; fRegional Cancer Therapies, Peritoneal Surface Metastasis Center, Kishiwada Tokushukai Hospital, Kishiwada, Japan; gAsian School of Peritoneal Surface Malignancy Treatment, Osaka, Japan; hDepartment of Surgery, Peritonectomy Unit, St George Hospital & University of New South Wales, Kogarah, NSW, Australia; iDepartment of Hematology, Oncology, and Cancer Immunology (CCM), Charité – Universitaetsmedizin Berlin, Berlin, Germany; jMassachusetts General Hospital Cancer Center, Boston, MA, USA; kHarvard Medical School, Boston, MA, USA Received: February 15, 2022 Accepted: February 22, 2022 Published online: March 8, 2022","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"120 - 125"},"PeriodicalIF":1.9,"publicationDate":"2022-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47491814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resection of Recurrent Pancreatic Cancer: Who Can Benefit? 复发性胰腺癌切除术:谁会受益?
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-02-01 DOI: 10.1159/000519754
Henrik Nienhüser, Markus W Büchler, Martin Schneider
{"title":"Resection of Recurrent Pancreatic Cancer: Who Can Benefit?","authors":"Henrik Nienhüser,&nbsp;Markus W Büchler,&nbsp;Martin Schneider","doi":"10.1159/000519754","DOIUrl":"https://doi.org/10.1159/000519754","url":null,"abstract":"<p><strong>Background: </strong>Recurrence after resection of pancreatic cancer occurs in up to 80% of patients in the first 2 years after complete resection. While most patients are not eligible for surgical treatment due to disseminated disease, a certain group of patients can be evaluated for re-resection of local recurrence. This review summarizes the current literature on surgical treatment of recurrent pancreatic cancer and potential prognostic factors.</p><p><strong>Summary: </strong>Re-resection of recurrent pancreatic cancer provides a significant survival benefit to selected patients with acceptable procedure-related mortality. Median overall survival after re-resection of recurrent pancreatic cancer is up to 28 months. The most relevant clinical parameters associated with a prognostic benefit are young patient age (<65 years), time to initial resection (>10 months), and preoperative chemotherapy before re-resection. Molecular markers are currently under investigation and might help to improve patient selection in the future.</p><p><strong>Key message: </strong>Re-resection of recurrent pancreatic cancer is safe and feasible in experienced hands. Selected patients benefit from surgical treatment, but future studies are needed to identify reliable prognostic markers predicting survival.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"42-48"},"PeriodicalIF":1.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874245/pdf/vis-0038-0042.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10595534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Metabolic Surgery: Paradigm Shift in Metabolic Syndrome/Diabetes Therapy. 代谢外科:代谢综合征/糖尿病治疗的范式转变。
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-02-01 DOI: 10.1159/000521707
Annika Rühle, Adrian T Billeter, Beat P Müller-Stich
{"title":"Metabolic Surgery: Paradigm Shift in Metabolic Syndrome/Diabetes Therapy.","authors":"Annika Rühle,&nbsp;Adrian T Billeter,&nbsp;Beat P Müller-Stich","doi":"10.1159/000521707","DOIUrl":"https://doi.org/10.1159/000521707","url":null,"abstract":"<p><strong>Background: </strong>Obesity and metabolic disorders as type 2 diabetes (T2D), nonalcoholic fatty liver disease (NAFLD) or better called metabolic dysfunction fatty liver disease (MAFLD), arterial hypertension (AHT), and obstructive sleep apnea syndrome (OSAS) show a rising prevalence. The increased cardiovascular risk is one of the main causes for death of obese, metabolic ill patients. Sustainable and efficient therapeutic options are needed.</p><p><strong>Summary: </strong>Metabolic surgery not only permits a substantial and lasting weight loss but also ameliorates metabolic co-morbidities and reduces cardiovascular risk and mortality of obese patients. Most existing data focused on T2D, but evidence for other metabolic co-morbidities such as NAFLD, AHT, and OSAS increase constantly. After metabolic surgery, glycemic control of diabetic patients is superior compared to conservative treatment. Also, diabetes related micro- and macrovascular complications are reduced after surgery, and the median life expectancy is over 9 years longer. In patients with MAFLD, metabolic surgery leads to reduction of steatosis and fibrosis while the risk to develop a hepatocellular carcinoma is reduced significantly. Patients with OSAS have an improved lung function and continuous pressure airway treatment during the night is unnecessary in many patients. Patients with AHT need significantly less or even no antihypertensive medication after surgery and the hazard ratio of death is reduced by 49.2%. Therefore, the focus in treating obese and metabolic ill patients is no longer on pure weight loss but on improvement of co-morbidities and reduction of mortality. This is reflected by the updated S3-guidelines of 2018 that provide nationally established consistent guidelines with clear indications for metabolic surgery no longer focusing on body mass index (BMI) only. This article aims to give an overview over the existing literature concerning surgical treatment options for metabolic syndrome.</p><p><strong>Key messages: </strong>Metabolic co-morbidities impact life-quality and life expectancy of obese patients. Metabolic surgery offers the chance to treat those metabolic co-morbidities independently of the preoperative BMI and should be considered early as a treatment option for obese patients.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"56-62"},"PeriodicalIF":1.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874241/pdf/vis-0038-0056.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10595535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery. 胰腺癌的分子谱分析:目前的作用及其对初级手术的影响。
IF 1.9 4区 医学
Visceral Medicine Pub Date : 2022-02-01 DOI: 10.1159/000519755
Carmen Mota Reyes, Alper Doğruöz, Rouzanna Istvanffy, Helmut Friess, Güralp O Ceyhan, Ihsan Ekin Demir
{"title":"Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery.","authors":"Carmen Mota Reyes,&nbsp;Alper Doğruöz,&nbsp;Rouzanna Istvanffy,&nbsp;Helmut Friess,&nbsp;Güralp O Ceyhan,&nbsp;Ihsan Ekin Demir","doi":"10.1159/000519755","DOIUrl":"https://doi.org/10.1159/000519755","url":null,"abstract":"<p><strong>Background: </strong>The advent of next-generation sequencing technologies has enabled the identification of molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) with different biological traits and clinically targetable features.</p><p><strong>Summary: </strong>Although current chemotherapy trials are currently exploiting this knowledge, these molecular subtypes have not yet sufficiently caught the attention of surgeons. In fact, integration of these molecular subtypes into the timing of surgery can in theory improve patient outcome. Here, we present the molecular subtypes of PDAC from the surgeon's perspective and a clinically applicable algorithm that integrates the molecular subtyping of PDAC preoperatively into the decision of primary surgery versus neoadjuvant therapy. Furthermore, we point out the potential of \"tailored\" (in addition to conventional) neoadjuvant treatment for exploiting the molecular subtypes of PDAC.</p><p><strong>Key messages: </strong>We believe that for surgeons, the preoperative knowledge on the subtype of PDAC can properly guide in deciding between upfront surgery versus neoadjuvant treatment for improving patient outcome.</p>","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"37-41"},"PeriodicalIF":1.9,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874240/pdf/vis-0038-0037.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10595533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma - Current Options and the Future Impact of Molecular Biological Profiling. 社论:胰腺导管腺癌的多模式治疗-目前的选择和分子生物学分析的未来影响
IF 1.8 4区 医学
Visceral Medicine Pub Date : 2022-02-01 Epub Date: 2022-01-24 DOI: 10.1159/000521419
Marko Kornmann, Alexander Kleger
{"title":"Editorial: Multimodality Treatment in Pancreatic Ductal Adenocarcinoma - Current Options and the Future Impact of Molecular Biological Profiling.","authors":"Marko Kornmann, Alexander Kleger","doi":"10.1159/000521419","DOIUrl":"10.1159/000521419","url":null,"abstract":"","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"1-3"},"PeriodicalIF":1.8,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42824818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信